Deal Snapshot
Dogma Therapeutics to Sell Oral PCSK9 Inhibitor Programme to AstraZeneca
Friday 18 September 2020

US-based Dogma Therapeutics has reached an agreement for the acquisition of its oral PCSK9 program by British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF), the company said.

Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones.

Date Published: 18/09/2020